Focused on the impact of inflammation with an immediate focus on mental health.
Systemic Chronic Inflammation is at the root of many diseases that collectively represent the leading causes of disability and mortality worldwide.
Chronic inflammation is known to negatively influence: cardiovascular disease; metabolic disorders; bone, muscular, & skeletal disease; neurological disorders; stages of various cancers; and mental health disorders. The anti-inflammatory market is expected to hit $135 Billion by 2026.
GoodCap is on a mission to develop a safer and more efficacious therapeutics to help those dealing with inflammation, with an initial focus of depression.
GoodCap’s lead program, GCAP001, is a novel combination drug product designed to significantly improve the benefits of psilocybin at non-intoxicating doses.
It is a multi-receptor agonist targeting both gastrointestinal inflammation and brain chemistry, impacting depression and with the potential to extend into other inflammatory based indications.
Cells in the gut produce the neurotransmitter serotonin, which affects diet and nutrition as well as mood signaling in the brain.
Diet and the intestinal microbiome can prompt immune cells to produce pro-inflammatory cytokines that can induce depression and anxiety.
Vagal tone bi-directional signal transduction can affect emotional regulation, depression, and even act as a measure of a person’s sensitivity to stress.
When inflammation is increased, depression increases.
✓ Sub-perceptive, non-hallucinogenic
✓ Rapid onset
✓ Alignment with current prescribing routines
✓ Greater efficacy
✓ Greater safety
✓ Greater tolerability
integration therapy (compared to flood dose therapy)
✓ Increased accessibility leading to larger market size
resulting in a greater reach and social impact
GoodCap formulations target inflammation pathways and cascades, offering potential across multiple therapeutic areas. Although initially focused on depression, there are many other indications available to be explored.